Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 14,350 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Digestive System Clear all
Completed Phase 2 Interventional

Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus

NCT00889486
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
TZP-102, Placebo
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 4, 2026, 2:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epidemiologic Study of Hepatocellular Carcinoma in the US

NCT02358070
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
35 Years to 84 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 4, 2026, 2:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing Interventions to Increase Colorectal Cancer Screening

NCT03200366
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Tailored DVD, Patient Navigation
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
45 Years to 75 Years
Enrollment
371 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 4, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Yogurt Study in Children 2-4 Years Old Attending Daycare

NCT00760851
View directory record Official record
Conditions
Infections, Respiratory, Diarrhea
Interventions
probiotic strain Bb-12, no Bb-12
Other
Lead sponsor
Georgetown University
Other
Eligibility
2 Years to 4 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2011 · Synced Oct 4, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

NCT02860546
View directory record Official record
Conditions
Refractory Metastatic Colorectal Cancer
Interventions
TAS-102, nivolumab
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 4, 2026, 2:55 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

NCT05308446
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Cetuximab, Encorafenib, Nivolumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
282
States / cities
Goodyear, Arizona • Carmichael, California • Dublin, California + 223 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 4, 2026, 2:55 AM EDT
Recruiting Not applicable Interventional

Gastric Focused Ultrasound Stimulation

NCT07851727
View directory record Official record
Conditions
Gastroparesis, Delayed Gastric Emptying
Interventions
Gastric Focused Ultrasound Stimulation
Device
Lead sponsor
Evan (Huiliang) Wang
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 4, 2026, 2:55 AM EDT
Not listed Phase 3 Interventional

Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas

NCT00005870
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, mitomycin C, rubitecan
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
San Ramon, California • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 4, 2026, 2:55 AM EDT
Withdrawn Phase 3 Interventional

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

NCT01447394
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Pegylated Interferon Lambda, Pegylated Interferon Alfa-2a, Ribavirin
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
San Diego, California • Rochester, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 4, 2026, 2:55 AM EDT
Completed Phase 3 Interventional

SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed

NCT00002551
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, levamisole hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2008
U.S. locations
35
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 4, 2026, 2:55 AM EDT
Withdrawn Not applicable Interventional

Strength for Health

NCT01882972
View directory record Official record
Conditions
Colon Cancer
Interventions
Exercise, Meditation
Behavioral
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 4, 2026, 2:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NCT05786924
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Interventions
S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
21
States / cities
Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 4, 2026, 2:55 AM EDT
Terminated Phase 2 Interventional

Imuran Dosing in Crohn's Disease Study

NCT00113503
View directory record Official record
Conditions
Crohn's Disease
Interventions
Azathioprine weight-based dose, Azathioprine individualised dose
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
10 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
12
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 4, 2026, 2:55 AM EDT
Recruiting Not applicable Interventional

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome

NCT05535361
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome
Device
Lead sponsor
Eclipse Regenesis, Inc.
Other
Eligibility
3 Months to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 4, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma

NCT00861783
View directory record Official record
Conditions
Hepatoma, Advanced Solid Tumor
Interventions
irinotecan and ON 01910.Na, oxaliplatin and ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 4, 2026, 2:55 AM EDT
Completed No phase listed Observational

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

NCT03892096
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Carcinoma, Metastatic Colorectal Cancer, Metastatic Breast Cancer
Interventions
Blood-based cell-free cfDNA qPCR assay
Diagnostic Test
Lead sponsor
Cadex Genomics
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
11
States / cities
Little Rock, Arkansas • Sunnyvale, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 4, 2026, 2:55 AM EDT
Completed Not applicable Interventional Results available

Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.

NCT01135186
View directory record Official record
Conditions
Gastroparesis
Interventions
sapropterin dihydrochloride
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 4, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab in Metastatic Anal Cancer

NCT02919969
View directory record Official record
Conditions
Anal Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 4, 2026, 2:55 AM EDT
Recruiting Phase 2 Interventional

High Dose Albumin in Refractory Ascites

NCT05867602
View directory record Official record
Conditions
Ascites
Interventions
Albumin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 4, 2026, 2:55 AM EDT
Completed Not applicable Interventional Results available

Mindfulness-Based Stress Reduction for Bowel Symptoms: Collection of Pilot Survey Data

NCT00880256
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
mindfulness-based stress reduction
Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 4, 2026, 2:55 AM EDT
Completed No phase listed Observational Results available

STeP IT UP CF: STimulating ImProved Health And Well-being In CysTic Fibrosis

NCT04018495
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 100 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 4, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

NCT02289898
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Demcizumab, Abraxane®, gemcitabine, Placebo
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Gilbert, Arizona • Burbank, California • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 4, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer

NCT04357587
View directory record Official record
Conditions
Rectal Neoplasms
Interventions
Pembrolizumab, External beam radiation, Capecitabine
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 4, 2026, 2:55 AM EDT
Not listed No phase listed Observational

Procurement of Blood Samples for a Biomedical Research Program on T Cell Functional Response to Chronic HBV Infection

NCT02017587
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Not listed
Lead sponsor
Vaccine and Gene Therapy Institute, Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 4, 2026, 2:55 AM EDT